U.S.-based venture capital firm Vivo Ventures has invested RMB190 million (approximately US$30 million) in Chinese pharmaceuticals company Shanghai Jingfeng Pharmaceutical. Vivo Ventures closed its seventh healthcare-focused fund at US$375 million in 2011 and plans to devote 45 percent of the fund’s capital to Chinese investments.